Boehringer Ingelheim and Circle Pharma have signed a partnership and licence agreement focused on developing a new cancer ...

Boehringer Ingelheim, a biopharmaceutical company active in ... the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. The WHO ...

The Phase III trials will evaluate survodutide in metabolic dysfunction-associated steatohepatitis (MASH), fibrosis and ...

Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim scientists, have developed a breakthrough small-molecule drug ...

The chronic and progressive inflammatory disease bronchiectasis is characterised by permanent bronchi dilation and by ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Boehringer Ingelheim and the WHO Foundation have partnered to promote equitable healthcare access and suicide prevention, with a focus on vulnera ...

Rapid Medical, Penumbra, and Phenox (for the DISTAL trial); reported consultancies for Medtronic, Stryker, and CSL Behring; participation in an advisory board for Alexion/Portola, Boehringer ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...